# Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

> **NCT00565968** · PHASE1 · COMPLETED · sponsor: **Duke University** · enrollment: 20 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** melphalan
- **DRUG:** sorafenib tosylate
- **GENETIC:** gene expression analysis
- **GENETIC:** protein expression analysis
- **GENETIC:** western blotting
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00565968
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-08
- **Final completion:** —
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00565968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00565968, "Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00565968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*